Abstract: The disclosure describes replication competent retroviral vectors (RCR) for gene therapy and gene delivery. The RCR includes an IRES sequence having 5-6A's in A-bulge of the bifurcation region.

Abstract: The disclosure provides for one or more immunosuppressive components associated with retroviral replicating vectors (RRVs) that contribute to RRV tumor specificity and efficacy.

Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.

Abstract: This disclosure provides recombinant replication competent retroviral vectors having increased stability. The disclosure further relates compositions and uses of such vectors in the treatment of disease and disorders.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: The disclosure provide cell lines and methods for the production of vectors and viral particles useful in diagnostics and therapeutics.

Abstract: This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Abstract: This disclosure provides modified cytosine deaminases(CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders. It further provides use of such modified CDs with a thymosin-alpha-1 polypeptide in the treatment of disease and disorders.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: A web-based mission certification quiz for educating various persons involved in a fundraising campaign is disclosed. A web-based method for educating solicitors, donors, participants and others involved in a fundraising campaign about the campaign's mission includes providing, on a website, information about the campaign's mission, taking, on the website, a mission certification quiz by answering one or more questions, wherein the questions are designed to test a participant's knowledge about the campaign's mission. The method further includes determining a final score based on the number of correct answers, and creating a mission certificate on the website based on the final score.

Abstract: A web-based mission certification quiz for educating various persons involved in a fundraising campaign is disclosed. A web-based method for educating solicitors, donors, participants and others involved in a fundraising campaign about the campaign's mission includes providing, on a website, information about the campaign's mission, taking, on the website, a mission certification quiz by answering one or more questions, wherein the questions are designed to test a participant's knowledge about the campaign's mission. The method further includes determining a final score based on the number of correct answers, and creating a mission certificate on the website based on the final score.

Abstract: A web-based automated method for validating a nonprofit organization is disclosed. In one embodiment, the method comprises the steps of applying online for a validation from a validator, receiving data pertaining to the nonprofit organization, analyzing the data to determine if the nonprofit organization is a bona fide organization, if the NPO is a bona fide organization, issuing the organization a validation, and if the NPO is not a bona fide organization, then denying the organization a validation. The method further comprises the step of providing an online seal of approval to the validated nonprofit organization. The method further comprises the step of displaying online the nonprofit organization data. The method further comprises the step of listing the validated nonprofit on an auction website. The method further comprises the step of receiving a donation from the sales proceeds of an auction.

Abstract: A system and method for efficiently managing a fundraising campaign over a wide-area network is disclosed. In accordance with one embodiment the invention, a web-based method for managing and supervising a plurality of volunteers, employees, staff, solicitors and/or other individuals engaged in solicitation on behalf of a nonprofit organization from prospects, each solicitor being assigned to solicit one or more prospects, the method utilizing one or more web pages on the Internet, comprises providing prospect data to the solicitor, providing one or more tasks assigned to the solicitor, the tasks including contacting the prospects, establishing a relationship with the prospects and soliciting donations from the prospects, and providing a status response including updates from the solicitor regarding the status of the tasks.

Abstract: A method for creating a virtual uniform resource locator (URL) for a customer wherein the virtual URL is hosted by an application service provider (ASP). The method comprises the steps of registering a wildcard domain name */ASP.net, the wildcard domain name directing requests of the form anyname/ASP.net to ASP's home page ASP.net, creating a virtual URL customer/ASP.net, wherein the customer is named before the ASP, creating a customer subdirectory ASP/customer.net, creating an index containing a list of customer subdirectories and a list of virtual URLs, wherein the index maps a virtual URL to a corresponding customer subdirectory, receiving an http request from a user for a virtual URL, determining the corresponding customer subdirectory for the requested virtual URL from the index, directing the user to the corresponding customer subdirectory.